四分之一剂量四药联合方案用于高血压初始治疗:安慰剂对照交叉随机试验及系统综述
在澳大利亚西悉尼社区四中心纳入未治疗高血压患者,随机交叉比较含四分之一剂量厄贝沙坦、氨氯地平、氢氯噻嗪和阿替洛尔的四联胶囊与安慰剂。四联胶囊安慰剂校正的24小时收缩压降低19 mm Hg(95%CI 14-23),诊室血压降低22/13 mm Hg(p<0·0001)。系统综述汇总四分之一剂量单药及两药联合试验,显示安慰剂校正降压效果分别为5/2 mm Hg和7/5 mm Hg。
要点
- 四联胶囊安慰剂校正24小时收缩压降低19 mm Hg(95%CI 14-23)。
- 四联胶囊治疗期间18例(100%)诊室血压<140/90 mm Hg,安慰剂期为6例(33%)(p=0·0013)。
- 系统综述中四分之一剂量单药及两药联合安慰剂校正降压分别为5/2 mm Hg和7/5 mm Hg。
核心结论
- 这项小型试验结合既往随机证据提示,四分之一剂量治疗的获益可能在不同药物类别间相加,并可能带来具有临床意义的血压降低。
- 作者认为需要进一步研究四联胶囊概念,以考察其与常规治疗方案的疗效对比及长期耐受性。
研究设计与样本
- 随机、安慰剂对照、双盲、交叉试验,在澳大利亚新南威尔士州西悉尼社区四个中心招募未治疗高血压患者。
- 四联胶囊为单粒胶囊含四种降压药各四分之一剂量:厄贝沙坦37·5 mg、氨氯地平1·25 mg、氢氯噻嗪6·25 mg、阿替洛尔12·5 mg。
- 参与者经计算机随机分配至四联胶囊或匹配安慰剂治疗4周,随后2周洗脱,再接受另一研究治疗4周。
- 主要结局为4周后安慰剂校正的24小时动态收缩压降低,采用意向性分析。
- 同时系统综述评估四分之一标准剂量降压治疗对比安慰剂的疗效与安全性试验。
主要发现
- 2014年11月至2015年12月筛查55例患者,其中21例接受随机化;平均年龄58岁(SD 11),基线平均诊室血压154(14)/90(11)mm Hg,24小时动态血压140(9)/87(8)mm Hg。
- 随机化后1例拒绝参与,2例因行政原因退出。
- 四联胶囊安慰剂校正的24小时收缩压降低19 mm Hg(95%CI 14-23),诊室血压降低22/13 mm Hg(p<0·0001)。
- 四联胶囊治疗期间18例中18例(100%)达到诊室血压<140/90 mm Hg,安慰剂治疗期间18例中6例(33%)达到(p=0·0013)。
- 系统综述纳入四分之一剂量单药试验36项(n=4721参与者)及两药四分之一剂量试验6项(n=312),安慰剂校正降压效果分别为5/2 mm Hg和7/5 mm Hg(均p<0·0001),两种方案均无副作用。
关键数值与推荐
- 四联胶囊安慰剂校正24小时收缩压降低19 mm Hg(95%CI 14-23)。
- 四联胶囊诊室血压降低22/13 mm Hg(p<0·0001)。
- 诊室血压<140/90 mm Hg达标:四联胶囊治疗期间18例中18例(100%)vs 安慰剂治疗期间18例中6例(33%)(p=0·0013)。
- 系统综述四分之一剂量单药安慰剂校正降压5/2 mm Hg(p<0·0001)。
- 系统综述两药四分之一剂量安慰剂校正降压7/5 mm Hg(p<0·0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这是一项小型试验(21例接受随机化)。
- 作者认为需要进一步研究四联胶囊概念,以考察其与常规治疗方案的疗效对比及长期耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Globally, most patients with hypertension are treated with monotherapy, and control rates are poor because monotherapy only reduces blood pressure by around 9/5 mm Hg on average. There is a pressing need for blood pressure-control strategies with improved efficacy and tolerability. We aimed to assess whether ultra-low-dose combination therapy could meet these needs. METHODS: We did a randomised, placebo-controlled, double-blind, crossover trial of a quadpill-a single capsule containing four blood pressure-lowering drugs each at quarter-dose (irbesartan 37·5 mg, amlodipine 1·25 mg, hydrochlorothiazide 6·25 mg, and atenolol 12·5 mg). Participants with untreated hypertension were enrolled from four centres in the community of western Sydney, NSW, Australia, mainly by general practitioners. Participants were randomly allocated by computer to either the quadpill or matching placebo for 4 weeks; this treatment was followed by a 2-week washout, then the other study treatment was administered for 4 weeks. Study staff and participants were unaware of treatment allocations, and masking was achieved by use of identical opaque capsules. The primary outcome was placebo-corrected 24-h systolic ambulatory blood pressure reduction after 4 weeks and analysis was by intention to treat. We also did a systematic review of trials evaluating the efficacy and safety of quarter-standard-dose blood pressure-lowering therapy against placebo. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12614001057673. The trial ended after 1 year and this report presents the final analysis. FINDINGS: Between November, 2014, and December, 2015, 55 patients were screened for our randomised trial, of whom 21 underwent randomisation. Mean age of participants was 58 years (SD 11) and mean baseline office and 24-h systolic and diastolic blood pressure levels were 154 (14)/90 (11) mm Hg and 140 (9)/87 (8) mm Hg, respectively. One individual declined participation after randomisation and two patients dropped out for administrative reasons. The placebo-corrected reduction in systolic 24-h blood pressure with the quadpill was 19 mm Hg (95% CI 14-23), and office blood pressure was reduced by 22/13 mm Hg (p<0·0001). During quadpill treatment, 18 (100%) of 18 participants achieved office blood pressure less than 140/90 mm Hg, compared with six (33%) of 18 during placebo treatment (p=0·0013). There were no serious adverse events and all patients reported that the quadpill was easy to swallow. Our systematic review identified 36 trials (n=4721 participants) of one drug at quarter-dose and six trials (n=312) of two drugs at quarter-dose, against placebo. The pooled placebo-corrected blood pressure-lowering effects were 5/2 mm Hg and 7/5 mm Hg, respectively (both p<0·0001), and there were no side-effects from either regimen. INTERPRETATION: The findings of our small trial in the context of previous randomised evidence suggest that the benefits of quarter-dose therapy could be additive across classes and might confer a clinically important reduction in blood pressure. Further examination of the quadpill concept is needed to investigate effectiveness against usual treatment options and longer term tolerability. FUNDING: National Heart Foundation, Australia; University of Sydney; and National Health and Medical Research Council of Australia.
引用
- Chow CK, Thakkar J, Bennett A, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017. PMID: 28190578. doi:10.1016/S0140-6736(17)30260-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。